Early Detection of Treatment Response to Mavacamten in Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Regurgitation Using Magnetocardiography

Key Points

• Mavacamten effectively reduces left ventricular outflow tract gradients in hypertrophic cardiomyopathy patients, suggesting its therapeutic value.
• Key evidence includes a notable LVOT gradient reduction after treatment with mavacamten, illustrating its effectiveness.
• Assessment using magnetocardiography shows promise as an objective monitoring tool for treatment responses in heart conditions.
• This research highlights the potential of mavacamten and MCG in managing hypertrophic obstruction and warrants further exploration.